Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Expectations too high. Reset your animus.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(48)
•••
Comment by Kd5513on Oct 13, 2022 1:56pm
134 Views
Post# 35022901

RE:RE:RE:RE:RE:RE:RE:RE:Expectations too high. Reset your animus.

RE:RE:RE:RE:RE:RE:RE:RE:Expectations too high. Reset your animus.
Nailed it RealityCheck!

Lack of insidier buying is very concerning. Even with limited windows for them to buy, the minimal buying in last 6 months at this discount share price is a huge red flag. This, added to saying nothing of value in CC is irritating to say the least.

One way they could demo confidence beyond just he was smiling when he said it or they said they were excited on the cc where we have to latch hold of any + thing we can as all indicators show this is underperfoming, would be to grant options at a higher price then current SP. Not sure this can be done. I know it won't be sadly........ just a thought
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities